Skip to main content

Table 2 Patient demographic and baseline characteristics.

From: Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study

 

HES 130/0.4

(n = 100)

NaCl 0.9%

(n = 96)

Gender, n (%)

  

   - Male

64 (64)

57 59)

   - Female

36 (36)

39 (41)

Age, years, mean ± SD

65.8 ± 15.4

65.9 ± 14.7

Race, n (%)

  

   - Caucasian

96 (96)

93 97)

   - Asian

1 (1)

1 (1)

   - Black

1 (1)

1 (1)

   - Other

2 (2)

1 (1)

Mean body mass index, kg/m2

26.2

26.0

Type of patient, n (%)

  

   - Medical

73 (73)

70 73)

   - Surgical

27 (27)

26 (27)

Renal impairment prior to screening*, n (%)

62 (63.9)

65 (68.4)

SAPS II prior to randomization, mean

50

53

SOFA at screening, mean

7.9

9.1

Fluid input prior to randomization, ml/kg body weight, mean ± SD

35.5 ± 25.3

39.9 ± 28.6

Origin of sepsis, n (%)

  

   - Lungs

53 (53)

58 (60)

   - Abdomen

24 (24)

18 (19)

   - Urogenital

8 (8)

14 (15)

   - Skin, bone and soft tissue

6 (6)

4 (4)

   - Other

5 (5)

2 (2)

   - Unknown

4 (4)

2 (2)

   - Neurological system

3 (3)

2 (2)

   - Ear nose and throat

2 (2)

0 (0)

Causative organism, n (%)

  

   - Gram-negative bacteria

35 (35)

41 (43)

   - Gram-positive bacteria

25 (25)

27 (28)

   - Other classes

40 (40)

32 (33)

  1. None of the differences were statistically significant; *known serum creatinine >3.39 mg/dl; SD, standard deviation; SAPS II, simplified acute physiology score; SOFA, sequential organ failure assessment; HES, hydroxyethyl starch; NaCI, sodium chloride.